Navigation Links
Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma

Boston, MA, San Antonio, TX (PRWEB) August 29, 2014

Intrinsic Imaging, an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant imaging core lab, announced today that it has been awarded an international Phase II clinical trial to assess a new treatment for patients with non-Hodgkin’s lymphoma.

Throughout this trial, Intrinsic Imaging will provide comprehensive imaging core lab services including, but not limited to, protocol and charter development, site qualification, site training and management, image transfer, blinding and processing as well as the specialized radiologic review of images acquired using positron emission tomography coupled with computed tomography (PET/CT), or PET coupled with magnetic resonance imaging (PET/MRI).

Intrinsic Imaging’s more than sixty board-certified radiologists have fellowship training in all subspecialty therapeutic areas including Oncology. The Oncology team consists of 12 full-time board-certified, fellowship trained radiologists all of whom have significant expertise in the evaluation of many cancers including but not limited to breast, cervical, colorectal, gastric, head and neck, lung, lymphoma, melanoma, ovarian, prostate, renal and thyroid.

“At Intrinsic Imaging, we are able to provide our wealth of oncology expertise to the design and management of clinical trials and to the determination of drug efficacy and/or disease progression,” said Todd A. Joron, BSc. MBA, President and Chief Operating Officer, Intrinsic Imaging. “Of the more than 1 million images reviewed annually by Intrinsic Imaging radiologists, 400,000 images are oncology related.”

Non-Hodgkin's lymphoma is cancer that originates in the lymphatic system. According to their April 2014 report, the Leukemia and Lymphoma Society estimate there are 558,340 people in the United States who are living with the disease or are in remission and another 70,800 new cases of non-Hodgkin’s lymphoma are expected to be diagnosed. Non-Hodgkin's lymphoma is the seventh most common cause of cancer related deaths in the United States.

About Intrinsic Imaging LLC
Located in Bolton, Massachusetts and San Antonio, Texas, Intrinsic Imaging is an FDA audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® 5 medical imaging core lab specializing in providing imaging core lab services for clinical trials. With its team of more than sixty board-certified diagnostic radiologists, robust and scalable clinical imaging technologies and our ISO certified and registered quality management systems, Intrinsic Imaging is ideally positioned to provide unprecedented imaging core lab services around the world. For more information, please visit

Read the full story at

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Quantitative Profiling of the Intrinsic Pathway of Apoptosis in Tumor Tissue Using Myriad RBM’s Multiplex ApoptosisMAP™, a New Biomarker Webinar by Xtalks
2. Intrinsically disordered proteins: A conversation with Rohit Pappu
3. A breakthrough in imaging gold nanoparticles to atomic resolution by electron microscopy
4. JH Technologies Brings an Expanded Level of Microscope and Imaging Expertise to Industrial Customers in Southern California
5. ChemImage Presents Latest Developments for in vitro Detection of Cancer Using Raman Chemical Imaging at International Conference on Raman Spectroscopy
6. Global Medical Imaging Reagents (Nanoparticles, Fluorescent Proteins, Fluorescent Dyes and Probes, Radiopharmaceuticals and Quantum Dots) Market - Forecast to 2019
7. Fastec Imaging Introduces the First High Speed Camcorder
8. Latest Technologies for Life-saving Applications on the Program at SPIE Medical Imaging
9. Founders Fund Backs Nanotronics Imaging
10. Smart Imaging Technologies and InvitroCue Team Up to Bring Digital Pathology to Asia
11. New venue, new conference, new courses, new technologies for Electronic Imaging 2014
Post Your Comments:
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/25/2015)... ANNAPOLIS, Md. , Nov. 25, 2015  PharmAthene, ... of Directors has adopted a stockholder rights plan (Rights ... its net operating loss carryforwards (NOLs) under Section 382 ... --> --> PharmAthene,s use of its ... an "ownership change" as defined in Section 382 of ...
(Date:11/25/2015)... 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS; ... and prospects remain fundamentally strong and highlights the ... recently received DSMB recommendation to continue the ZoptEC ... of the final interim efficacy and safety data ... in men with heavily pretreated castration- and Taxane-resistant ...
(Date:11/24/2015)... , Nov. 24, 2015  Asia-Pacific (APAC) holds ... organisation (CRO) market. The trend of outsourcing to ... margins but higher volume share for the region ... scale, however, margins in the CRO industry will ... Market ( ), finds that the ...
Breaking Biology Technology:
(Date:11/4/2015)... , November 4, 2015 ... market report published by Transparency Market Research "Home Security Solutions ... and Forecast 2015 - 2022", the global home security solutions ... bn by 2022. The market is estimated to expand ... from 2015 to 2022. Rising security needs among customers ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
Breaking Biology News(10 mins):